Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P0DPB6
UPID:
RPAC2_HUMAN
Alternative names:
AC19; DNA-directed RNA polymerase I subunit D; RNA polymerase I 16 kDa subunit; RPC16; hRPA19
Alternative UPACC:
P0DPB6; Q5TBX2; Q96BR3; Q9Y2S0
Background:
DNA-directed RNA polymerases I and III subunit RPAC2, also known as AC19, plays a pivotal role in the transcription of DNA into RNA, utilizing ribonucleoside triphosphates as substrates. It is a core component of RNA polymerases I and III, essential for synthesizing ribosomal RNA precursors and small RNAs, including 5S rRNA and tRNAs.
Therapeutic significance:
RPAC2's involvement in Treacher Collins syndrome 2, a craniofacial development disorder, highlights its critical role in human health. Understanding the role of RPAC2 could open doors to potential therapeutic strategies for this and related conditions.